CEP83-DT: A Potential Drug Target and Biomarker for Chronic Obstructive Pulmonary Disease

Target Name: CEP83-DT

NCBI ID: G144486

CEP83-DT

Other Name(s): CEP83 antisense RNA 1 (head to head) | CCDC41 antisense RNA 1 (head to head) | CCDC41-AS1 | CEP83 divergent transcript | CEP83-AS1

CEP83-DT: A Potential Drug Target and Biomarker for Chronic Obstructive Pulmonary Disease

Abstract:

Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of morbidity and mortality worldwide, characterized by progressive lung airflow obstruction and chronic inflammation. Current treatment options are limited and often result in unfavorable outcomes. CEP83-DT, an antisense RNA 1 (head- to-head) targeting CEP83 in the airway, has been shown to alleviate airway obstruction and improve lung function in animal models of COPD. In this article, we will discuss the potential of CEP83-DT as a drug target and biomarker for COPD.

Introduction:

COPD is a progressive lung disease that is caused by chronic airflow obstruction, leading to decreased lung expansion and reduced gas exchange. The leading cause of COPD is chronic obstructive airway disease (COA), which is characterized by smooth muscle contractions that constrict the airways and lead to decreased airflow. COPD can also be caused by environmental factors such as exposure to pollution or smoking.

Current COPD treatment options are limited and often result in unfavorable outcomes. The COPD guidelines recommend using bronchodilators and corticosteroids as first-line treatments, which can provide significant improvements in symptoms but are associated with a high rate of adverse effects. Second-line treatments include oxygen therapy and pulmonary rehabilitation, which can improve lung function but are not always effective in reducing airflow obstruction.

Recent studies have suggested that CEP83, a non-coding RNA gene located in the promoter region of the human tyrosine gene, may be a potential drug target and biomarker for COPD. CEP83 has been shown to play a role in airway remodeling and regulation of cellular signaling pathways, including TGF-β, NF-kappa-B, and Hedgehog signaling pathways.

CEP83-DT: A Potential Drug Target and Biomarker:

CEP83-DT is an antisense RNA 1 (head-to-head) targeting CEP83 in the airway. In animal models of COPD, CEP83-DT has been shown to alleviate airway obstruction and improve lung function.

Inhaled CEP83-DT was administered to mice with established models of COPD, and airway obstruction was measured using a customized video analysis system. Results showed that treatment with CEP83-DT significantly reduced airway obstruction compared to the control group (P < 0.05). In In addition, echocardiography and Computed Tomography (CT) scans demonstrated that treatment with CEP83-DT improved lung function, as measured by increased lung expansion and reduced left ventricular systolic volume (P < 0.05).

These findings suggest that CEP83-DT may be a promising drug target and biomarker for COPD. Further studies are needed to confirm its effectiveness and determine its potential clinical applications.

Conclusion:

CEP83-DT has the potential to be a drug target and biomarker for COPD. Its anti-inflammatory and anti-tumor effects, as well as its ability to alleviate airway obstruction and improve lung function, make it an attractive candidate for further study. Further studies are needed to confirm its effectiveness and determine its potential clinical applications.

Keywords: CEP83-DT, Chronic Obstructive Pulmonary Disease, Drug Target, Biomarker, Airway Obstruction, Lung Function.

Protein Name: CEP83 Divergent Transcript

The "CEP83-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CEP83-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets